auto
Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click
here to learn how we are responding.
COVID-19 continues to affect us. Get reliable updates and resources on COVID-19 and a vaccine option by Pfizer & BioNTech sent straight to your inbox. CIBINQO (abrocitinib) is a prescription medicine to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.
Please rotate your device to continue viewing this site.
ABOUT ECZEMA (atopic dermatitis)
If your eczema (atopic dermatitis) feels like a burden, you should know you’re not alone. In fact, there are about 6.6 million adults living with moderate-to-severe eczema in the U.S. right now.
It's also common to have difficulty managing your condition. In one study, about 200 doctors surveyed found that nearly 59% of patients with moderate-to-severe eczema were not well controlled.
In the U.S., about
people (12 years and older) have
If you've experienced the effects of eczema (atopic dermatitis), you know how much of a burden it can be—and you're not alone. In fact, there are about 8.7 million people (age 12+) living with moderate-to-severe eczema in the U.S. right now.
It’s also common to have difficulty managing symptoms. One survey of about 200 doctors found that for nearly 59% of adult patients with moderate-to-severe eczema, the condition wasn’t well controlled.
You’ve probably learned a lot about eczema already. But thanks to recent information and research, you may want to take a fresh look at its
potential causes and symptoms. The more you know, the more prepared you can be to have meaningful conversations about treatment options with your or your teen's doctor.
A study of 1,064
Eczema can look and feel different from person to person. The signs and symptoms of moderate-to-severe eczema may include:
Eczema may appear different depending on skin tone.
In lighter skin tones, eczema often looks red.
In darker skin tones, eczema may appear as darker patches, and redness may not be as visible.
Photos enhanced to illustrate moderate-to-severe eczema.
In lighter skin tones, eczema often looks red.
Photos enhanced to illustrate moderate-to-severe eczema.
In darker skin tones, eczema may appear as darker patches, and redness may not be as visible.
Photos enhanced to illustrate moderate-to-severe eczema.
In a study of 602 people with eczema,
If you have eczema, you can see it’s a skin condition. You've probably also learned it may be
IRREGULAR IMMUNE RESPONSE
Eczema can be caused in part by
INFLAMMATION
This immune response is
SIGNS OF ECZEMA
Inflammation contributes to
If you are like many people with
moderate-to-severe eczema, you may have struggled with your condition.
Be sure to tell your doctor about your symptoms and the signs of eczema on your skin’s surface. Also talk about any impact of eczema they may not see, like loss of sleep. This can help your doctor recommend a treatment plan that’s right for you.
If you are like many people with
moderate-to-severe eczema, you may have struggled with your condition.
Be sure to tell your doctor about your eczema signs and symptoms. This can help them recommend a treatment plan that’s right for you.
Talk to your doctor if your eczema feels uncontrolled, even after you've tried other medicines, including biologics.
We’ll help you track symptoms, consider your goals, and note questions to ask—whether your conversation is virtual or in person.
There can be more to eczema than meets the eye
8.7 MILLION
moderate-to-severe eczema
If you struggle with this chronic
condition, you are not alone
Managing eczema? Stay informed
people showed
do not have control over their moderate-to-severe eczema
Which signs and symptoms
do you experience?
among the 206 who describe their eczema
as moderate or severe
What causes eczema?
caused by various factors, such as your genes or triggers in your environment.
But did you know
your immune system and inflammation may also play a role?
an irregular immune response
within the skin.
thought to contribute to
inflammation in the skin.
the signs of eczema you see
on the skin’s surface.
Thinking about talking with your doctor?
Get our full guide for talking with your doctor
CIBINQO may cause serious side effects, including:
Serious infections. CIBINQO can lower your immune system’s ability to fight infections. Do not start CIBINQO if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body, have occurred in people taking CIBINQO or other similar medicines. Some people have been hospitalized or died from these infections. Your risk of developing shingles may increase while taking CIBINQO.
Your healthcare provider should test you for TB before treatment with CIBINQO and monitor you closely for signs and symptoms of TB infection during treatment.
Before and after starting CIBINQO, tell your doctor right away if you have an infection, are being treated for one, or have symptoms of an infection, including:
CIBINQO can make you more likely to get infections or worsen infections you have. If you get a serious infection, your healthcare provider may stop treatment with CIBINQO until your infection is controlled.
There is an increased risk of death in people 50 years and older who have at least one heart disease (cardiovascular) risk factor and are taking a Janus kinase (JAK) inhibitor (such as CIBINQO).
Cancer and immune system problems. CIBINQO may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People, especially current or past smokers, have a higher risk of certain cancers, including lymphoma and lung cancers, while taking a JAK inhibitor. Follow your healthcare provider’s advice about having your skin checked for skin cancer during treatment. Limit the amount of time you spend in sunlight and avoid using tanning beds or sunlamps. When in the sun, wear protective clothing and use SPF 30+ sunscreen. This is especially important if you have very fair skin or a family history of skin cancer. Tell your healthcare provider if you have ever had any type of cancer.
There is an increased risk of major cardiovascular (CV) events such as heart attack, stroke or death in people 50 years and older who have at least one heart disease (CV) risk factor and are taking a JAK inhibitor, especially for current or past smokers.
Some people taking CIBINQO have had major cardiovascular events.
Get emergency help right away if you develop any symptoms of a heart attack or stroke while taking CIBINQO, including:
Blood clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking CIBINQO. This may be life-threatening. Blood clots in the veins of the legs and lungs have happened more often in people 50 years and older, with at least one heart disease (CV) risk factor, taking a JAK inhibitor. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.
Stop taking CIBINQO and get medical help right away if you have any signs and symptoms of blood clots including swelling, pain, or tenderness in one or both legs; sudden, unexplained chest or upper back pain; shortness of breath or difficulty breathing.
Changes in certain laboratory test results. Your doctor should do blood tests before and during treatment with CIBINQO to check your lymphocyte, neutrophil, red blood cell, and platelet counts. You should not take CIBINQO if these counts are too low. Your healthcare provider may stop treatment for a period of time if there are changes in these blood test results.
Increased cholesterol levels. You may also have increases in the amount of fat found in your blood. Your doctor should check your cholesterol about 4 weeks after you start CIBINQO and then as needed.
During the first 3 months of treatment with CIBINQO, do not take medicines that prevent blood clots except low-dose aspirin (≤81 mg daily), if prescribed.
Before taking CIBINQO, tell your healthcare provider if you:
The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count.
Separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people treated with CIBINQO. Call your healthcare provider right away if you have any sudden changes in your vision.
CIBINQO may cause fertility problems in females, which may affect the ability of females to get pregnant. Talk to your healthcare provider if you have concerns about fertility.
These are not all of the possible side effects of CIBINQO.
What is CIBINQO?
CIBINQO is a prescription medicine to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.
It is not known if CIBINQO is safe and effective in children under 12 years of age.
Please see full Prescribing Information, including BOXED WARNING, and Medication Guide.
Learn more about financial assistance options and other resources by talking to a Patient Support Representative.
Call 1-833-956-DERM
(1-833-956-3376)
Monday-Friday, 8:00
AM-8:00
PM ET
Eligibility required for financial assistance.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only).
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
Eligibility required for financial assistance.
You are encouraged to report adverse events related to Pfizer products by calling
1-800-438-1985 (U.S. only).
If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
CIBINQO may cause serious side effects, including:
Serious infections. CIBINQO can lower your immune system’s ability to fight infections. Do not start CIBINQO if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body, have occurred in people taking CIBINQO or other similar medicines. Some people have been hospitalized or died from these infections. Your risk of developing shingles may increase while taking CIBINQO.
Your healthcare provider should test you for TB before treatment with CIBINQO and monitor you closely for signs and symptoms of TB infection during treatment.
Before and after starting CIBINQO, tell your doctor right away if you have an infection, are being treated for one, or have symptoms of an infection, including:
CIBINQO can make you more likely to get infections or worsen infections you have. If you get a serious infection, your healthcare provider may stop treatment with CIBINQO until your infection is controlled.
There is an increased risk of death in people 50 years and older who have at least one heart disease (cardiovascular) risk factor and are taking a Janus kinase (JAK) inhibitor (such as CIBINQO).
Cancer and immune system problems. CIBINQO may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People, especially current or past smokers, have a higher risk of certain cancers, including lymphoma and lung cancers, while taking a JAK inhibitor. Follow your healthcare provider’s advice about having your skin checked for skin cancer during treatment. Limit the amount of time you spend in sunlight and avoid using tanning beds or sunlamps. When in the sun, wear protective clothing and use SPF 30+ sunscreen. This is especially important if you have very fair skin or a family history of skin cancer. Tell your healthcare provider if you have ever had any type of cancer.
There is an increased risk of major cardiovascular (CV) events such as heart attack, stroke or death in people 50 years and older who have at least one heart disease (CV) risk factor and are taking a JAK inhibitor, especially for current or past smokers.
Some people taking CIBINQO have had major cardiovascular events.
Get emergency help right away if you develop any symptoms of a heart attack or stroke while taking CIBINQO, including:
Blood clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking CIBINQO. This may be life-threatening. Blood clots in the veins of the legs and lungs have happened more often in people 50 years and older, with at least one heart disease (CV) risk factor, taking a JAK inhibitor. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.
Stop taking CIBINQO and get medical help right away if you have any signs and symptoms of blood clots including swelling, pain, or tenderness in one or both legs; sudden, unexplained chest or upper back pain; shortness of breath or difficulty breathing.
Changes in certain laboratory test results. Your doctor should do blood tests before and during treatment with CIBINQO to check your lymphocyte, neutrophil, red blood cell, and platelet counts. You should not take CIBINQO if these counts are too low. Your healthcare provider may stop treatment for a period of time if there are changes in these blood test results.
Increased cholesterol levels. You may also have increases in the amount of fat found in your blood. Your doctor should check your cholesterol about 4 weeks after you start CIBINQO and then as needed.
During the first 3 months of treatment with CIBINQO, do not take medicines that prevent blood clots except low-dose aspirin (≤81 mg daily), if prescribed.
Before taking CIBINQO, tell your healthcare provider if you:
The most common side effects of CIBINQO include common cold, nausea, headache, herpes simplex including cold sores, increased blood level of creatine phosphokinase, dizziness, urinary tract infection, tiredness, acne, vomiting, mouth and throat pain, flu, stomach flu, bacterial skin infection, high blood pressure, allergic skin rash to something you contacted, stomach pain, shingles, and low platelet count.
Separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people treated with CIBINQO. Call your healthcare provider right away if you have any sudden changes in your vision.
CIBINQO may cause fertility problems in females, which may affect the ability of females to get pregnant. Talk to your healthcare provider if you have concerns about fertility.
These are not all of the possible side effects of CIBINQO.
What is CIBINQO?
CIBINQO is a prescription medicine to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis) that did not respond to other treatment and is not well controlled with prescription medicines, including biologics, or when they cannot be tolerated.
It is not known if CIBINQO is safe and effective in children under 12 years of age.
Please see full Prescribing Information, including BOXED WARNING, and Medication Guide.
Patients should always ask their doctors for medical advice about adverse events.
This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.
CIBINQO (abrocitinib) is available in 50 mg, 100 mg, and 200 mg pills.
